Reversible posterior leukoencephalopathy syndrome (RPLS) is being increasingly described with various etiologies even in the absence of hypertension. We present an 11-year-old patient with acute lymphoblastic leukemia who presented with seizures while on treatment with L-asparaginase. MRI showed bilaterally symmetrical nonenhancing occipital lesions characteristic of RPLS. L-Asparaginase-induced RPLS is a rare cause of neurological symptoms in patients on induction chemotherapy.

Keywords:
L-Asparaginase, Acute lymphoblastic leukemia, Reversible posterior leukoencephalopathy, MRI
1.
Edwards MJJ, Walker R, Vinnicombe S, Barlow C, MacCallum P, Foran JM: Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma. Ann Oncol 2001;12:1327–1329.
2.
Hinchey J, Chaves C, Appignani B, Bareen J, Pao L, Wang A, Pesin MS, Lamy C, Mas JL, Caplan LR: A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494–500.
3.
Bakshi R, Bates VE, Mechtle LL, Kinkel RP, Kinkel RW: Occipital lobe seizures as the major clinical manifestation of reversible posterior leukoencephalopathy syndrome: Magnetic resonance imaging findings. Epilepsia 1998;3:295–299.
4.
Schwartz RB, Bravo SM, Klufas RA, Hsu L, Barnes PD, Robson CD, Antin JH: Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol 1995;165:627–631.
5.
Haskell CM, Canellos GP, Laventhal BG, Carbone PP, Block JB, Serpick AA, Selawry OS: L-asparaginase: Therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 1969;281:1028–1034.
6.
Shin RK, Stern JW, Janss AJ, Hunter JV, Liu GT: Reversible posterior leukoencephalopathy during the treatment of acute lymphoblastic leukemia. Neurology 2001;56:388–391.
7.
Feinberg WM, Swenson MR: Cerebrovascular complications of L-asparaginase therapy. Neurology 1988;38:127–133.
8.
Foreman NK, Mahomaud HH, Langston JW: 99Tcm-HMPAO SPECT and magnetic resonance studies in L-asparaginase induced cerebrovascular accident. Br J Radiol 1992;20:78–81.
9.
Bushara KO, Rust RS: Reversible MRI lesions due to pegaspargase treatment of non-Hodgkin’s lymphoma. Pediatr Neurol 1997;17:185–187.
10.
Ay H, Buonanno FS, Schaefer PW, Le DA, Wang B, Gonzales RG, Koroshetz WJ: Posterior leukoencephalopathy without severe hypertension: Utility of diffusion-weighted MRI. Neurology 1998;51:1369–1376.
11.
Weingarten K, Barbut D, Fillipi C, Zimmerman RD: Acute hypertensive encephalopathy: Findings on spin-echo and gradient-echo MR imaging. AJR Am J Roentgenol 1994;162:665–670.
12.
Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T, Yanagi T, Sobue G: Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 1998;19:415–417.
13.
Dillon WP, Rowley H: The reversible posterior cerebral edema syndrome. AJNR Am J Neuroradiol 1998;19:591.
14.
Vaughn DJ, Jarvic JG, Hackney D, Peters S, Stadtmauer AE: High-dose cytarabine neurotoxicity: MR findings during the acute phase. AJNR Am J Neuroradiol 1993;14:1014–1016.
15.
Delanty N, Vaughan C, Frucht S, Stubgen P: Erythropoietin-associated hypertensive posterior leukoencephalopathy. Neurology 1997;49:686–689.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.